0001782999-24-000004 | 6-K | XBRL Viewer

Subsidiary Preferred Shares - Schedule of Subsidiary Preferred Shares, Minimum Liquidation Preference (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Minimum liquidation preference [Line Items]
Total minimum liquidation preference	$ 76,721	$ 8,621

Subsidiary Preferred Shares (Tables)

6 Months Ended

Jun. 30, 2024

Subsidiary Preferred Shares [Abstract]

Schedule of Subsidiary Preferred Share Balances

The fair value of all subsidiary preferred shares as of June 30, 2024 and December 31, 2023, is as follows:


	2024 $	2023 $
As of June 30, 2024 and December 31, 2023

Entrega	169	169

Seaport	69,713	—





Total subsidiary preferred share balance	69,882	169

Schedule of Subsidiary Preferred Shares, Minimum Liquidation Preference

As of June 30, 2024 and December 31, 2023, the minimum liquidation preference reflecting the amounts that would be payable to the subsidiary preferred holders upon a liquidation event of the subsidiaries, is as follows:


	2024 $	2023 $
As of June 30, 2024 and December 31, 2023

Entrega	2,216	2,216
Follica	6,405	6,405
Seaport	68,100	—





Total minimum liquidation preference	76,721	8,621

Schedule of Changes in the Value of Subsidiary Preferred Shares

For the six months ended June 30, 2024, the Group recognized the following changes in the value of subsidiary preferred shares:


			Subsidiary Preferred Shares $

Balance as of December 31 2023			169
Issuance of new preferred shares			68,100

Increase/(decrease) in value of preferred shares measured at fair value*			1,613





Balance as of June 30			69,882

* The changes in fair value of preferred shares are included in total finance income/(costs) – fair value accounting in the Condensed Consolidated Statement of Comprehensive Income/(Loss).

Share-based Payments (Tables)

6 Months Ended

Jun. 30, 2024

Share-based Payments [Abstract]

Schedule of Share-Based Payment Expense as Reflected in the Consolidated Statement of Income/(Loss)

The following table provides the classification of the Group’s consolidated share-based payment expense as reflected in the Condensed Consolidated Statement of Comprehensive Income/(Loss):


Six months ended June 30,	2024 $	2023 $
General and administrative	4,471	1,121
Research and development	176	135
Total	4,648	1,256

Cover (6-K)	6 Months Ended
Cover (6-K)	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Entity File Number	001-39670
Entity Registrant Name	PURETECH HEALTH PLC
Entity Central Index Key	0001782999
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Current Fiscal Year End Date	--12-31

General information (Policies)	6 Months Ended
General information (Policies)	Jun. 30, 2024
Accounting Policies 1 [Abstract]
Basis of accounting	Basis of accounting These Interim Financial Statements have been prepared in accordance with International Accounting Standards (IAS) 34 Interim Financial Reporting as adopted for use in the UK and also comply fully with IAS 34 as issued by the International Accounting Standards Board ("IASB"). The Interim Financial Statements should be read in conjunction with the Group’s Consolidated Financial Statements as of and for the year ended December 31, 2023. The Interim Financial Statements do not include all the information required for a complete set of financial statements in accordance with International Financial Reporting Standards ("IFRS"). However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual consolidated financial information included in the Annual Report and Accounts for the year ended December 31, 2023, which was prepared in accordance with UK-adopted International Financial Reporting Standards and also complied fully with International Financial Reporting Standards as issued by the IASB. Certain amounts in the Condensed Consolidated Financial Statements and accompanying notes may not add due to rounding. All percentages have been calculated using unrounded amounts. These Condensed Consolidated Financial Statements do not comprise statutory accounts within the meaning of Section 435 of the Companies Act 2006. The comparative figures for the six months ended June 30, 2023 are not the Group’s statutory accounts for that financial year. Those accounts were reported upon by the Group’s auditors and delivered to the registrar of companies. The report of the auditors was unqualified, did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report and did not contain statements under Section 498 (2) or (3) of the Companies Act 2006. The unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Material Accounting policies	Material Accounting policies There have been no significant changes in the Group’s accounting policies from those disclosed in our Consolidated Financial Statements as of and for the year ended December 31, 2023. The significant accounting policies used for half-year financial reporting are disclosed in Note 1, Material Accounting policies of the accompanying notes to the Consolidated Financial Statements included in our 2023 Annual Report and Accounts.

Non-Controlling Interest (Tables)

6 Months Ended

Jun. 30, 2024

Non-Controlling Interests [Abstract]

Schedule of Aggregation of Subsidiaries with Material Non-controlling Interests Before Intra-group Eliminations

The following table summarizes the financial information related to Seaport, the Group's only subsidiary with significant non-controlling interest as of June 30, 2024.

For the period ended June 30, 2024

Non-Controlling Interest

Statement of Comprehensive Income/(Loss)

Total revenue

—

Income/(loss) for the period

(12,332)

Total comprehensive income/(loss) for the period

(12,332)

Statement of Financial Position

Total assets

102,494

Total liabilities

79,070

Net assets/(liabilities)

23,424

Investments Held at Fair Value - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jul. 02, 2024	Mar. 31, 2024
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments	$ 163	$ (167)
Reduced amount			$ 10,399
Bristol Myers Squibb
Investments held at fair value [Line Items]
Business combination, share price paid (in dollars per share)					$ 330
Vedanta
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments	(3,648)	(2,171)
Karuna
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments	11,813	21,458
Number of associate's common stock held at fair value			886,885
Proportion of ownership interest in investee (as a percent)			2.30%
Sale of equity instruments in other entities (in shares)					886,885,000
Vor
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments	(3,340)	(9,512)
Akili (Common)
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments	$ (985)	$ (354)
Sale of equity instruments in other entities (in shares)				12,527,476

Investment in Notes from Associates (Tables)

6 Months Ended

Jun. 30, 2024

Investment in Notes from Associates [Abstract]

Schedule of Investments in Associates

Following is the activity in respect of investments in notes from associates during the period. The fair value of the $16,212 notes from associates as of June 30, 2024 is determined using unobservable Level 3 inputs. See Note 13. Financial Instruments for additional information.


Investment in notes from associates			$




Balance as of December 31, 2023 and January 1, 2024			4,600


Changes in the fair value of the notes			11,612
Balance as of June 30, 2024			16,212

Taxation - Narrative (Details)	6 Months Ended
Taxation - Narrative (Details)	Jun. 30, 2024	Jun. 30, 2023
Taxation [Line Items]
Effective tax rate	11.20%	(85.90%)

Subsidiary Preferred Shares - Schedule of Changes in the Value of Subsidiary Preferred Shares (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Changes in the value of subsidiary preferred shares [Roll Forward]
Beginning balance	$ 169
Increase/(decrease) in value of preferred shares measured at fair value	1,613
Ending balance	$ 69,882

General information - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies 1 [Abstract]
Short-term investments	$ 191,938	$ 136,062

Subsidiary Preferred Shares

6 Months Ended

Jun. 30, 2024

Subsidiary Preferred Shares [Abstract]

Subsidiary Preferred Shares

In April 2024, Seaport closed a Series A-2 preferred share financing with aggregate proceeds of $100,100 of which $68,100 was from outside investors and $32,000 was from the Group. As of June 30, 2024, the Group held equity ownership in Seaport of 57.7 percent on a diluted basis.

Preferred shares issued by subsidiaries often contain redemption and conversion features that are assessed under IFRS 9 in conjunction with the host preferred share instrument. This balance represents subsidiary preferred shares issued to third parties.

The subsidiary preferred shares are redeemable upon the occurrence of a contingent event, other than full liquidation of the subsidiaries, that is not considered to be within the control of the subsidiaries. Therefore, these subsidiary preferred shares are classified as liabilities. These liabilities are measured at fair value through profit and loss. The preferred shares are convertible into ordinary shares of the subsidiaries at the option of the holders and are mandatorily convertible into ordinary shares under certain circumstances. Under certain scenarios, the number of ordinary shares receivable on conversion will change and therefore, the number of shares that will be issued is not fixed. As such, the conversion feature is considered to be an embedded derivative that normally would require bifurcation. However, since the preferred share liabilities are measured at fair value through profit and loss, as mentioned above, no bifurcation is required.

The preferred shares are entitled to vote with holders of common shares on an as converted basis.

The fair value of all subsidiary preferred shares as of June 30, 2024 and December 31, 2023, is as follows:


	2024 $	2023 $
As of June 30, 2024 and December 31, 2023

Entrega	169	169

Seaport	69,713	—





Total subsidiary preferred share balance	69,882	169

As is customary, in the event of any voluntary or involuntary liquidation, dissolution or winding up of a subsidiary, the holders of outstanding subsidiary preferred shares shall be entitled to be paid out of the assets of the subsidiary available for distribution to shareholders and before any payment shall be made to holders of ordinary shares. A merger, acquisition, sale of voting control or other transaction of a subsidiary in which the shareholders of the subsidiary immediately before the transaction do not own a majority of the outstanding shares of the surviving company shall be deemed to be a liquidation event. Additionally, a sale, lease, transfer or other disposition of all or substantially all of the assets of the subsidiary shall also be deemed a liquidation event.


	2024 $	2023 $
As of June 30, 2024 and December 31, 2023

Entrega	2,216	2,216
Follica	6,405	6,405
Seaport	68,100	—





Total minimum liquidation preference	76,721	8,621

For the six months ended June 30, 2024, the Group recognized the following changes in the value of subsidiary preferred shares:


			Subsidiary Preferred Shares $

Balance as of December 31 2023			169
Issuance of new preferred shares			68,100

Increase/(decrease) in value of preferred shares measured at fair value*			1,613





Balance as of June 30			69,882

* The changes in fair value of preferred shares are included in total finance income/(costs) – fair value accounting in the Condensed Consolidated Statement of Comprehensive Income/(Loss).

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2024

Financial Instruments [Abstract]

Schedule of Fair Value Measurement Methods

The approaches, in order of strongest fair value evidence, are detailed as follows:


Valuation Method			Description
Market – Backsolve			The market backsolve approach benchmarks the original issue price (OIP) of the company’s latest funding transaction as current value.
Market/Asset – PWERM			Under a PWERM, the company value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise. Possible future outcomes can include IPO scenarios, potential SPAC transactions, merger and acquisition transactions as well as other similar exit transactions of the investee.
Income Based – DCF			The income approach is used to estimate fair value based on the income streams, such as cash flows or earnings, that an asset or business can be expected to generate.

The methods are detailed as follows:


Allocation Method			Description
OPM			The OPM model treats preferred stock as call options on the enterprise’s equity value, with exercise prices based on the liquidation preferences of the preferred stock.


PWERM			Under a PWERM, share value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise, as well as the rights of each share class.
Hybrid			The hybrid method is a combination of the PWERM and OPM. Under the hybrid method, multiple liquidity scenarios are weighted based on the probability of the scenario's occurrence, similar to the PWERM, while also utilizing the OPM to estimate the allocation of value in one or more of the scenarios.

The Group measures fair value using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements:


Fair Value Hierarchy Level			Description
Level 1			Inputs that are quoted market prices (unadjusted) in active markets for identical instruments.
Level 2			Inputs other than quoted prices included within Level 1 that are observable either directly (i.e. as prices) or indirectly (i.e. derived from prices).
Level 3			Inputs that are unobservable. This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instruments' valuation.

Schedule of Changes in Financial Liabilities, Level 3 Fair Value, Subsidiary Preferred Shares

The following table summarizes the changes in the Group’s subsidiary preferred shares measured at fair value, which are categorized as Level 3 in the fair value hierarchy:


			Subsidiary Preferred Shares $


















Balance at December 31, 2023 and January 1, 2024			169
Value at issuance			68,100





Change in fair value			1,613


Balance at June 30, 2024			69,882

Schedule of Changes in Assets, Level 3 Fair Value, Investments Held at Fair Value

The following table summarizes the changes in all the Group’s investments held at fair value categorized as Level 3 in the fair value hierarchy:


			$










Balance at December 31, 2023			24,872





Gain/(loss) on changes in fair value			(3,796)


Balance as of June 30, 2024 before allocation of equity method loss to LTI			21,076
Equity method loss recorded against LTI			(172)
Balance as of June 30, 2024 after allocation of equity method loss to LTI			20,904

Financial Instruments - Schedule of Fair Value Measurement and Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Financial Instruments - Fair value Measurement and Classification [Line Items]
Short-term investments	$ 191,938	$ 136,062

Non-Controlling Interest - Schedule of Changes in Equity Classified Non-controlling Ownership Interests in Subsidiaries (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Non-Controlling Interests [Line Items]
Expiration of share options in subsidiary	$ 0	$ 0

Subsidiary Preferred Shares - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Apr. 30, 2024
Subsidiary Preferred Shares [Line Items]
Proceeds from investors		$ 68,100
Proceeds from group		$ 32,000
Seaport Therapeutics
Subsidiary Preferred Shares [Line Items]
Ownership interest	57.70%

Investments Held at Fair Value (Tables)

6 Months Ended

Jun. 30, 2024

Investments held at fair value [Abstract]

Schedule of Investments Held at Fair Value

Activities related to such investments during the periods are shown below:


Investments held at fair value			$



















Balance as of December 31, 2023 and January 1, 2024			317,841

Sale of Karuna shares			(292,672)
Gain realised on sale of investments			151



Gain – change in fair value through profit and loss			3,882

Balance as of June 30, 2024 before allocation of equity method loss to long-term interest ("LTI")			29,202
Equity method loss recorded against LTI			(172)
Balance as of June 30, 2024 after allocation of equity method loss to LTI			29,030

Share-based Payments - Narrative (Details)	1 Months Ended			6 Months Ended
Share-based Payments - Narrative (Details)	Jun. 30, 2024 USD ($) pence	Jun. 30, 2023	Jun. 30, 2015	Jun. 30, 2024 USD ($) pence simulation shares	Jun. 30, 2023 USD ($)	May 31, 2024 USD ($)	Mar. 31, 2024 USD ($)	Feb. 29, 2024 USD ($)	Dec. 31, 2023 USD ($)	May 31, 2023 USD ($)
Share-based Payments Table [Line Items]
Share-based payment arrangements, percentage of common shares outstanding		0.10	0.10
Share-based compensation arrangement by share-based payment award, award vesting period				4 years
Share-based awards expiration period	5 years			10 years
Number of common shares redeemable from each RSU (in shares) \| shares				1
Award settlement, price per share \| pence	1			1
Number of simulations \| simulation				100,000
Settlement of liability (in shares)						$ 646,000	$ 655,000	$ 424,000		$ 424,000
Expense (income) in respect of RSU liability award				$ 609,000	$ (485,000)
Current liabilities from share based payment transactions	$ 1,886,000			1,886,000					$ 1,281,000
Liability for share-based awards	$ 1,550,000			$ 1,550,000					3,501,000
Liabilities from share based payment transactions, performance and market conditions met									$ 1,281,000
Minimum
Share-based Payments Table [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period				1 year
Maximum
Share-based Payments Table [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period				3 years

Investments Held at Fair Value

6 Months Ended

Jun. 30, 2024

Investments held at fair value [Abstract]

Investments Held at Fair Value

Investments held at fair value include both unlisted and listed securities held by the Group. These investments, which include interests in Akili, Vor, Sonde, Vedanta and other insignificant investments, are initially measured at fair value and are subsequently re-measured at fair value at each reporting date with changes in the fair value recorded through profit and loss. See Note 13. Financial Instruments for information regarding the valuation of these instruments. Activities related to such investments during the periods are shown below:


Investments held at fair value			$



















Balance as of December 31, 2023 and January 1, 2024			317,841

Sale of Karuna shares			(292,672)
Gain realised on sale of investments			151



Gain – change in fair value through profit and loss			3,882

Balance as of June 30, 2024 before allocation of equity method loss to long-term interest ("LTI")			29,202
Equity method loss recorded against LTI			(172)
Balance as of June 30, 2024 after allocation of equity method loss to LTI			29,030

Vedanta

On March 1, 2023 Vedanta issued convertible debt to a syndicate of investors. The Group did not participate in this round of financing. As part of the issuance of the debt, the convertible debt holders were granted representation on Vedanta's Board of Directors and the Group lost control over the Vedanta's Board of Directors and the power to direct the relevant Vedanta activities. Consequently, Vedanta was deconsolidated on March 1, 2023 and its results of operations were included in the Condensed Consolidated Financial Statements through the date of deconsolidation.

Following deconsolidation, the Group still has significant influence over Vedanta through its voting interest in Vedanta and its remaining representation on Vedanta's Board of Directors. However, the Group only holds convertible preferred shares in Vedanta that do not provide their holders with access to returns associated with a residual equity interest, and as such, are accounted for under IFRS 9, as investments held at fair value with changes in fair value recorded in profit and loss. Under IFRS 9, the preferred share investments are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest.

Upon deconsolidation, the Group derecognized its assets, liabilities and non-controlling interest in respect of Vedanta and recorded its aforementioned investment in Vedanta at fair value. The deconsolidation resulted in a gain of $61,787.

During the six months ended June 30, 2024 and June 30, 2023, the Group recognized a loss of $3,648 and $2,171, respectively for the changes in the fair value of the investment in Vedanta that was included in gain/(loss) on investments held at fair value within the Condensed Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Vedanta was $10,505 and $14,153 as of June 30, 2024 and December 31, 2023, respectively.

Karuna

As of December 31, 2023, the Group held 886,885 shares or 2.3 percent of total outstanding Karuna common stock with fair value of $280,708. In March 2024, Karuna common shares were acquired by Bristol Myers Squibb ("BMS") for $330 per share in accordance with the terms of a definitive merger agreement signed in December 2023. As a result of this transaction, the Group received total proceeds of $292,672 before income tax in exchange for its holding of 886,885 shares of Karuna common stock.

During the six months ended June 30, 2024 and 2023, the Group recognized a gain of $11,813 and $21,458, respectively, for the changes in the fair value of its investment in Karuna that was included in gain/(loss) on investments held at fair value within the Condensed Consolidated Statement of Comprehensive Income/(Loss).

Sonde

On May 25, 2022, Sonde completed a Series B preferred share financing, which resulted in the Group losing control over Sonde and the deconsolidation of Sonde.

Following deconsolidation, the Group still had significant influence in Sonde through its voting interest in Sonde and its remaining representation on Sonde's Board of Directors. The Group holds Preferred A-1, A-2 and B shares. The Preferred A-1 shares have the same terms as common stock, and provide their shareholders with access to returns associated with a residual equity ownership in Sonde. Consequently, the investment in Preferred A-1 shares is accounted for under the equity method. See Note 5. Investments in Associates. The convertible Preferred A-2 and B shares, however, do not provide their shareholders with access to returns associated with a residual equity interest, and as such, are accounted for under IFRS 9, as investments held at fair value with changes in fair value recorded in profit and loss. Under IFRS 9, the A-2 and B preferred share investments are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest.

During the six months ended June 30, 2024 and 2023, the Group recognized a gain of $163, and a loss of $167, respectively, for the change in the fair value of its investment in Sonde that were included in gain/(loss) on investments held at fair value within the Condensed Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Sonde was $10,571 and $10,408 as of June 30, 2024 and December 31, 2023, respectively. As the Group’s investment in

Sonde is considered to be a long term interest, a loss of $172 from Sonde’s equity method of accounting was applied to the investment balance, reducing the balance to $10,399.

Vor

During the six months ended June 30, 2024 and 2023, the Group recognized a loss of $3,340 and $9,512, respectively, for the change in the fair value of its investment in Vor that was included in gain/(loss) on investments held at fair value within the Condensed Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Vor was $2,672 and $6,012 as of June 30, 2024 and December 31, 2023, respectively.

Akili

During the six months ended June 30, 2024 and 2023, the Group recognized a loss of $985 and $354, respectively, for the changes in the fair value of its investment in Akili that were included in gain/(loss) on investments held at fair value within the Condensed Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Akilli was $5,437 and $6,422 as of June 30, 2024 and December 31, 2023, respectively.

On July 2, 2024, Akili was acquired by Virtual Therapeutics. As a result of this transaction, the Group received total proceeds of $5,437 before income taxes in exchange for its holding of 12,527,476 shares of Akili common stock.

Finance Income/(Costs), net - Schedule of Finance Income (Cost) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Finance income
Interest income from financial assets	$ 11,732	$ 7,731
Finance costs
Contractual interest expense on notes payable	(328)	(82)
Gain/(loss) on foreign currency exchange	(33)	(76)
Gain/(loss) from change in fair value of warrant liability	0	33
Gain/(loss) from change in fair value of preferred shares	(1,613)	2,617
Total finance costs - non cash interest expense related to sale of future royalties	$ (10,551)	$ (3,726)

Investments Held at Fair Value - Schedule of Investments Held at Fair Value (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Investments held at fair value [Line Items]
Balance as of June 30, 2024 before allocation of equity method loss to long-term interest ("LTI")	$ 29,202

Label

Element

Value

Number Of Reportable Segment

ptv_NumberOfReportableSegment

Number Of Reportable Segment

ptv_NumberOfReportableSegment

Number Of Ordinary Shares Issued To Settle Share-based Payment Awards

ptv_NumberOfOrdinarySharesIssuedToSettleShareBasedPaymentAwards

161,678

Number Of Ordinary Shares Issued To Settle Share-based Payment Awards

ptv_NumberOfOrdinarySharesIssuedToSettleShareBasedPaymentAwards

599,512

Number Of Shares, Acquired

ptv_NumberOfSharesAcquired

33,500,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

$ 337,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

87,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

424,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

424,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

1,512,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

(211,000)

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

1,301,000

Increase decrease through settlement of restricted stock units

ptv_IncreaseDecreaseThroughSettlementOfRestrictedStockUnits

1,301,000

Adjustments For Finance Costs (Income)

ptv_AdjustmentsForFinanceCostsIncome

1,468,000

Adjustments For Finance Costs (Income)

ptv_AdjustmentsForFinanceCostsIncome

(5,316,000)

Cash And Cash Equivalents, And Short-term Investments